AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Patent issued protecting interleukin-9 activity-reducing vaccine technology.
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Genaera Corp. (GENR) announced issuance by the United States Patent and Trademark Office of patent number 6,645,486 covering claims for reducing the activity of interleukin-9 (IL-9) comprising administering a conjugate of IL-9 and a carrier sufficient to induce production of IL-9 specific antibodies that bind to and reduce IL-9 activity.
The patent is entitled "Method of Treatment with IL-9 Conjugate." The patent, assigned to the Ludwig Institute of Cancer Research, is subject to a license granted to Genaera.
"Treatment of asthma and other IL-9-related conditions using a vaccine technology ...
- Genaera Announces Patent Issued Protecting Interleukin-9 Vaccine Technology.
- Press release article from: PR Newswire November 13, 2003 700+ words
...antibodies which bind to and reduce IL-9 activity. The patent is entitled "Method of Treatment with IL-9 Conjugate." The patent...Treatment of asthma and other IL-9 related conditions using a vaccine technology to generate specific antibodies...
- CEL-SCI receives United States patent for use of peptide vaccine technology for...
- Newspaper article from: BIOTECH Patent News February 1, 2006 700+ words
...E.A.P.S. peptide vaccine technology in the areas of autoimmunity...associated with an increase in IL-13 in both the sera and heart tissue and of IL-1 alpha in the sera of the...Rose's laboratory with IL-13 knockout-mice (mice...
- Mindset and New York University Collaborate on Novel Vaccine Technology For...
- Press release article from: PR Newswire July 22, 2002 700+ words
...worldwide exclusive licensee of a breakthrough vaccine technology for the treatment of Alzheimer's disease...541 2726 E-mail: info@mindset.co.il Website: http://www.mindset.co.il About Alzheimer's Disease Alzheimer's...
- CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious...
- Press release article from: PR Newswire June 9, 2008 700+ words
...favorable new developments in the LEAPS(TM) heteroconjugate vaccine technology developed by CEL-SCI at the FOCIS Immunology meeting in...LEAPS vaccines, the cytokine that drives a Th1 response, IL-12, and the primary cytokine that mediates its effects...
- Nabi Biopharmaceuticals Licenses Its Staphylococcus aureus Whole Cell Vaccine...
- Press release article from: PR Newswire April 14, 2003 700+ words
...worldwide license to its whole cell vaccine technology for the prevention and treatment...aureus polysaccharide conjugate vaccine) technology that is currently in late stages...S. aureus whole cell veterinary vaccine technology to Pharmacia Animal Health, a leading...
- LigoCyte to Develop MSU Vaccine Technology for Oral/Nasal Delivery Of...
- Press release article from: PR Newswire December 7, 2000 700+ words
...today that it will develop "M Cell" vaccine technology from Montana State University (MSU...Biology at MSU and inventor of the M Cell vaccine technology. "M Cell vaccine technology will potentially address this unmet need...
- Needham, Mass., Firm Expected to License Vaccine Technology to Defense Company.
- Newspaper article from: Knight Ridder/Tribune Business News October 10, 2001 700+ words
...announce today that it is licensing its vaccine technology to a Department of Defense contractor...an excellent way to leverage our vaccine technology into another research area that we...to the company believe Avant's vaccine technology would be useful in developing an...
- AVANT Licenses Vaccine Technology to U.S. Department of Defense Contractor,...
- Press release article from: PR Newswire October 10, 2001 700+ words
...use certain components of AVANT's vaccine technology. Financial terms of the agreement...the world, and we believe that our vaccine technology can contribute significantly to this...an excellent way to leverage our vaccine technology into another research area that we...
Source: HighBeam Research, Patent issued protecting interleukin-9 activity-reducing vaccine...